Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5- fluorouracil and induces protective immunity

Cancer Gene Therapy

Volumn 7, Issue 4, 2000, Pages 637-643

  Kawamura, Kiyoko ^a   Tasaki, Kentaro ^a,b   Hamada, Hirofumi ^c,d   Takenaga, Keizo ^e   Sakiyama, Shigeru ^f   Tagawa, Masastoshi ^a,f  

^a Division of Pathology   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

^e Division of Chemotherapy   (Japan)

^f CHIBA CANCER CENTER   (Japan)

Author keywords

5 fluorouracil; Gene therapy; Protective immunity; Suicide gene; Uracil phosphoribosyltransferase

Indexed keywords

BACTERIAL ENZYME; DRUG METABOLITE; FLUOROURACIL; FLUOROURIDINE PHOSPHATE; GANCICLOVIR; OROTATE PHOSPHORIBOSYLTRANSFERASE; PHOSPHORIBOSYLTRANSFERASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; TUMOR IMMUNITY;

ANIMALIA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; HERPES; MAMMALIA; MURINAE; MUS MUSCULUS; SIMPLEXVIRUS;

EID: 0034087221     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700154     Document Type: Article

References (28)

1. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther. 1994;5:153-164.
2. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31-45.
3. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
4. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer. 1997;33:1005-1016.
5. McMaster RA, Saylors RL, Jones KE, et al. Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gene Ther. 1998;9:2253-2261.
6. Jensen KF, Mygind B. Different oligomeric states are involved in the allosteric behavior of uracil phosphoribosyltransferase from Escherichia coli. Eur J Biochem. 1996; 240:637-645.
7. Suttle DP, Bugg BY, Winkler JK, Kanalas JJ. Molecular cloning and nucleotide sequence for the complete coding region of human UMP synthase. Proc Natl Acad Sci USA. 1988;85:1754-1758.
8. Peters GJ, Braakhuis BJM, de Bruijn EA, et al. Enhanced therapeutic efficacy of 5′deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes. Br J Cancer. 1989;59: 327-334.
9. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
10. Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res. 1980;40: 2142-2146.
11. Ebina T, Murata K. Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents. Jpn J Cancer Res. 1992;83:775-782.
12. Andersen PS, Smith JM, Mygind B. Characterization of the upp gene encoding uracil phosphoribosyltransferase of Escherichia coli K12. Eur J Biochem. 1992;204:51-56.
13. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques. 1989;7:980-990.
14. Laskin JD, Evans RM, Slocum HK, et al. Basis for natural variation in sensitivity to 5-fluorouracil in mouse and human cells in culture. Cancer Res. 1979;39:383-390.
15. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 1995;154:5302-5312.
16. Rogers RP, Ge J-Q, Holley-Guthrie E, et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther. 1996;7:2235-2245.
17. Ge K, Xu L, Zheng Z, et al. Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int J Cancer. 1997;71:615-679.
18. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 1997;4:113-117.
19. Lawrence TS, Rehemtulla A, Ng EY, et al. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res. 1998;58:2588-2593.
20. Domin BA, Mahony WB, Zimmerman TP. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem Pharmacol. 1993;46:503-510.
21. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
22. Link CJ Jr, Levy JP, McCann LZ, Moorman DW. Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J Surg Oncol. 1997;64:289-294.
23. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 1998;58:1946-1951.
24. Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996;87:212-220.
25. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
26. Bonnekoh B, Greenhalgh DA, Chen SH, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defense in the B16 melanoma model. J Invest Dermatol. 1998;110:867-871.
27. Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther. 1996;3:373-384.
28. Lanzavecchia A. Immunology: Licence to kill. Nature. 1998;393:413-414.